Nanosonics Limited (NAN.AX)
ASX · AUD · Healthcare · Medical Instruments & Supplies
A$3.12 (+0.65%) as of
Key statistics
- Market cap
- 933.40M
- P/E (TTM)
- 52.00
- Forward P/E
- 60.00
- EPS (TTM)
- 0.0600
- Dividend yield
- 0.00%
- 52-week range
- 2.6400 – 4.6600
- Beta
- 1.15
- Revenue (TTM)
- 203.89M
- Profit margin
- 8.75%
- Analyst target
- A$3.88
- Volume
- 934.45k
About Nanosonics Limited
Nanosonics Limited engages in the manufacture and commercialization of infection control and decontamination products and related technologies in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. It offers trophon, an automated ultrasound probe high-level disinfection device built on hydrogen peroxide chemistry with integrated digital traceability solutions, as well as related consumables and accessories. The company also provides infection control and decontamination products and related technologies. In addition, it is involved in the research, development, and commercialization of the CORIS system, an automated technology designed to transform flexible endoscope reprocessing. The company was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Headquarters
- Macquarie Park, NSW, Australia
- Employees
- 508
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.